puromycin

Puromycin (NSC-3055) is an antibiotic protein synthesis inhibitor. It inhibits protein synthesis by binding to RNA. It also serves as an anticancer drug by suppressing the growth and metastasis in esophagus cancer cells by Akt phosphorylation. It is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis.

Puromycin dihydrochloride (CL13900 dihydrochloride) is a cinnamamide adenosine antibiotic and an inhibitor of protein synthesis. Puromycin dihydrochloride inhibits protein synthesis by binding to RNA and has antitumor and antitrypanosomal activity.

O-Propargyl-Puromycin (OP-puro) is a potent protein synthesis inhibitor, a puromycin acetylene analog.

Puromycin aminonucleoside (NSC 3056) is an aminonucleoside antibiotic and a purine analog of puromycin. It can reversibly inhibit dipeptidyl peptidase and cytosolic alanine aminopeptidase, increase podocyte permeability by regulating ZO-1 in an oxidative stress-dependent manner, induce apoptosis, and promote the secretion of migrasomes. It is commonly used to induce nephrotic syndrome models in research.

Puromycin-d3 is the deuterated form of Puromycin. Derived from the bacterium Streptomyces, Puromycin belongs to the aminoglycoside class of antibiotics and acts as an inhibitor of protein synthesis.

Puromycin-d3 (dihydrochloride) is the deuterated form of Puromycin dihydrochloride. Puromycin dihydrochloride (CL13900 dihydrochloride) functions as an aminonucleoside antibiotic that inhibits protein synthesis.

PSA-IN-1 (compound 19) is an inhibitor of puromycin-sensitive aminopeptidase (PSA) with an IC50 value of 7 nM, and it exhibits analgesic activity.

Lincophenicol is an Escherichia coli ribosomal peptidyltransferase-catalyzed puromycin reaction inhibitor.

Tripeptidyl peptidase II (TPPII) is a serine peptidase of the subtilisin-type which removes tripeptides from the free NH2 terminus of oligopeptides. AAF-CMK is an irreversible inhibitor of TPPII commonly used at 10-100 μM. It does not significantly interfere with the chymotrypsin-like activity of the proteasome. AAF-CMK also inhibits bleomycin hydrolase and puromycin-sensitive aminopeptidase when used at 50 μM.

Tosedostat (CHR-2797) is an orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Intracellularly converted into the poorly membrane-permeable active metabolite (CHR-79888), it inhibits puromycin-sensitive aminopeptidase (PuSA) and leukotriene A4 (LTA4) hydrolase. This inhibition in tumor cells may lead to amino acid deprivation, suppressed protein synthesis, increased proapoptotic protein Noxa levels, and ultimately, cell death.

Triptriolide inhibits puromycin aminonucleoside (PAN)-induced apoptosis in mouse podocytes by modulating Bcl-2 family proteins and suppressing Caspase-3. It also promotes cell survival and protects podocyte function by activating the TAK1-NF-κB signaling pathway and upregulating the podocyte protein podocin.